Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China

Fan, Weiguang; Wang, Xiaodong; Zhang, Yuchen; Meng, Jie; Su, Miaomiao; Yang, Xin; Shi, Haoxi; Shi, Peipei; Lu, Xinli

doi:10.3389/fgene.2022.975397

Cited by 5 publications

(6 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The convenient transport network in this region enables geographical mobility, and creates opportunities for dual or multiple infections within the MSM population. This has led to the emergence and prevalence of new recombinant strains in MSM in recent years, such as CRF103_01B, CRF123_0107, CRF01_AE/B and CRF01_ AE/CRF07_BC Zhou et al, 2020;Xing et al, 2021;Fan et al, 2022a,b;Xing et al, 2022). The emergence of new recombinant forms have increased the diversity of HIV-1 isolates prevalent in Hebei province, indicating the further molecular monitoring of HIV-1 diversity is vital in the region.…”

Section: Discussionmentioning

confidence: 99%

Current Progress in Genomic and Genetic Research on Human Viral Diseases

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

Section: Discussionmentioning

confidence: 99%

Current Progress in Genomic and Genetic Research on Human Viral Diseases

2024

Frontiers Research Topics

View full text Add to dashboard Cite

show abstract

“…INSTIs, new generations of protease inhibitors (PIs), among others were introduced and promoted nationally, which substantially expanding access to ART initiation and switching for PLHIV in China 14 . Since 2015, raltegravir (RAL) and dolutegravir (DTG) have been used in PLHIV in China 15 – 18 . In 2018, single-regimen pills containing emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) and INSTI gained widespread useage 15 – 18 .…”

Section: Introductionmentioning

confidence: 99%

“…Since 2015, raltegravir (RAL) and dolutegravir (DTG) have been used in PLHIV in China 15 – 18 . In 2018, single-regimen pills containing emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) and INSTI gained widespread useage 15 – 18 .…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, long-term INSTI-based prescriptions are expensive in China. In 2015, two INSTIs received regulatory approval and began to be used in PLHIV in China 15 – 18 . However, the landscape of fully reimbursed ART in China before 2021 included two NNRTIs (EFV and NVP), and a single PI (lopinavir [LPV]); along with several nucleotide reverse transcriptase inhibitors (NRTIs).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China

Wu,

et al. 2023

Nat Commun

View full text Add to dashboard Cite

Despite the proven virological advantages, there remains some controversy regarding whether first-line integrase strand transfer inhibitors (INSTIs)-based antiretroviral therapy (ART) contributes to reducing mortality of people living with HIV (PLHIV) in clinical practice. Here we report a retrospective study comparing all-cause mortality among PLHIV in China who were on different initial ART regimens (nevirapine, efavirenz, dolutegravir, lopinavir, and others [including darunavir, raltegravie, elvitegravir and rilpivirine]) between 2017 and 2019. A total of 41,018 individuals were included across China, representing 21.3% of newly reported HIV/AIDS cases collectively in the country during this period. Only the differences in all-cause mortality of PLHIV between the efavirenz group and the nevirapine group, the dolutegravir group and the nevirapine group, and the lopinavir group and the nevirapine group, were observed in China. After stratifying the cause of mortality, we found that the differences in mortality between initial ART regimens were mainly observed in AIDS-related mortality.

show abstract

“…In 2019, WHO first-line ART changed to dolutegravir, an integrase strand transfer inhibitor (INSTI). However, for individuals who develop resistance [ 3 , 4 ] or treatment-emergent toxicity on DTG [ 5 ], bPIs continue to have a significant role in the management of human immunodeficiency virus (HIV) in sub-Saharan Africa.…”

mentioning

confidence: 99%

Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin

Gausi,

Mugerwa,

Siccardi

et al. 2023

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent use of rifampicin and protease inhibitors. We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin. Methods DERIVE (NCT04121195, EDCTP) was a dose-escalation trial in people with human immunodeficiency virus (HIV) on atazanavir/ritonavir-based antiretroviral therapy (ART) in Uganda. Four intensive pharmacokinetic (PK) visits were performed: PK1 300/100 mg OD (baseline); PK2 300/100 mg OD with rifampicin 600 mg; PK3 300/100 mg twice a day (BID) with rifampicin 600 mg OD; PK4 300/100 mg BID with rifampicin 1200 mg OD. Dolutegravir 50 mg BID throughout the study period ensured participants remained protected from subtherapeutic atazanavir concentrations. The data were interpreted with noncompartmental analysis. The target minimum concentration was atazanavir's protein-adjusted IC90 (PA-IC90), 0.014 mg/L. Results We enrolled 26 participants (23 female) with median (range) age 44 (28–61) years and weight 67 (50–75) kg. Compared with PK1, atazanavir Ctau, and AUC were significantly reduced at PK2 by 96% and 85%, respectively. The escalation to BID dosing (PK3) reduced this difference in Ctau, and AUC24 to 18% lower and 8% higher, respectively. Comparable exposures were maintained with double doses of rifampicin. Lowest Ctau during PK1, PK3, and PK4 were 12.7-, 4.8-, and 8.6-fold higher than PA-IC90, respectively, whereas 65% of PK2 Ctau were below the limit of quantification (0.03 mg/L), hence likely below PA-IC90. No participant developed significant elevation of liver enzymes, reported a serious adverse event (SAE) or experienced rebound viraemia. Conclusions Twice daily atazanavir/ritonavir during rifampicin co-administration was well tolerated and achieved plasma concentrations above the target. Clinical Trials Registration NCT04121195. Registered on 09 October 2019, https://clinicaltrials.gov/ct2/show/NCT04121195.

show abstract

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China

Cited by 5 publications

References 132 publications

Current Progress in Genomic and Genetic Research on Human Viral Diseases

Current Progress in Genomic and Genetic Research on Human Viral Diseases

Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China

Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin

Contact Info

Product

Resources

About